ELISA Technologies, Inc. – Trademark Portfolio
Entity Type: 03
ELISA Technologies, Inc. owns a portfolio of 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as ALLER-TEK, ELISA-TEK, EZ GLUTEN, and MELISA-TEK. Of these, 4 are registered. The portfolio spans 3 Nice Classification classes, led by Class 1 (Chemicals) and Class 42 (Computer & Scientific). Headquartered in Gainesville, FL.
2501 NW 66th Ct
Gainesville, FL 32653
Showing of trademarks Trademarks
Trademark Classifications
ELISA Technologies, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does ELISA Technologies, Inc. have?
ELISA Technologies, Inc. has 10 U.S. trademarks filed with the USPTO. Of these, 4 registered, 2 abandoned, 4 cancelled.
What trademark classes does ELISA Technologies, Inc. file in?
ELISA Technologies, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are ELISA Technologies, Inc.'s most well-known trademarks?
ELISA Technologies, Inc.'s registered trademark portfolio includes well-known marks such as ALLER-TEK, ELISA-TEK, EZ GLUTEN, and MELISA-TEK. These are among 4 currently registered trademarks in the portfolio.
What is ELISA Technologies, Inc.'s trademark registration success rate?
ELISA Technologies, Inc. has a 40% trademark registration rate, with 4 out of 10 resolved applications resulting in successful registration. Currently, 0 applications are pending review.